reports
- Jacob Mekhael
MaaT Pharma Uneventful 3Q25 cash and revenues
MaaT reported uneventful 3Q25 cash and revenues, where its cash and cash equivalents came in at € 22.4m, providing the company with a cash runway until the end of February 2026. We note that continued growth in revenues from MaaT013's early access program (only billable in France) is a positive sign ahead of its potential EMA approval expected mid-2026. MaaT did not provide a pipeline update, though it has previously guided for results from the investigator initiated phase 2a (PICASSO) trial of ...
- Jacob Mekhael
ASH abstracts: Autolus, Galapagos, MaaT
The abstracts for presentations at the American Society of Haematology conference (ASH, 6-9 December) became available yesterday during the day (HERE). While we may have to wait until the actual conference for the latest datasets, here in this note are some key takeaways for our coverage including updates from Autolus (new data for Aucatzyl in paediatric ALL, real world data in adult ALL, amongst others), Galapagos (additional CAR-T data in r/r MCL and r/r DLBCL) and MaaT (longer follow up from ...
- ING Helpdesk
Benelux Morning Notes
AB InBev: The interim is back. Arcadis: Slow return to organic growth, FCF disappoints. Ayvens: Keeping its promise. dsm-firmenich: Waiting for Godot. D'Ieteren: Boyd prelim 3Q25, $1.3bn M&A deal, NYSE listing, $780m capital increase. Flow Traders: Down but not out. Ontex: FY25F guidance confirmed despite a modestly softer 3Q25. Recticel: Weak 3Q25 but comforting outlook. Shell plc: Solid story with cash continuing to come in strongly. TKH Group: Preview - subsea remains in foc...
- Wim Hoste
Recticel FIRST LOOK: 3Q top line below expectations, FY guidance maint...
Recticel saw 3Q revenue decline by 1% which was below our and consensus forecasts. Recticel reiterated FY25 adjusted EBITDA guidance calling for c. 10% growth. The strategic growth projects in the US (Insulated Panels Plant) and Belgium (Recycling plant) are progressing according to plan. While we still believe in the strategic attractiveness of the insulation market and Recticel's offering, we deem short term valuation multiples are about fair so we maintain our Hold rating and € 11 target pric...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Thomas Couvreur
- Wim Hoste
- Jacob Mekhael
- Kristof Samoy
- Thomas Couvreur
- Wim Lewi
- Jacob Mekhael
MaaT Pharma Safety board recommends MaaT033 phase 2b continues as plan...
MaaT announced that the independent data safety monitoring board (DSMB) has completed the second pre-planned safety interim analysis of the ongoing randomised controlled phase 2b (PHOEBUS) trial of MaaT033 (microbiome therapy, oral capsule) in patients undergoing an allogeneic hematopoietic stem cell transplantation (allo-HSCT), and recommended that the study continue as planned. There were no safety concerns and no excessive mortality related to MaaT033 as of today. The upcoming routine DSMB re...
- Maxime Stranart
- Stijn Demeester
- Jacob Mekhael
- Mathijs Geerts Danau
Life Sciences Conference 25 Sep 2025
KBC Securities will host its annual life sciences conference on 25 September in Brussels. The event will include 14 exciting companies, both public and private, from the BeNeLux ecosystem and beyond. In this conference note, we provide an overview of the attending companies, as well as an outlook on KBC Securities' life sciences broader coverage.
- Jacob Mekhael
- Mathijs Geerts Danau
MaaT Pharma 1H25 results confirm timelines, runway to end Feb 2026
MaaT reported 1H25 results with € 2.4m in revenues from the early access program (1H24: € 1.7m) for MaaT013 in aGvHD, which points to increased demand for the product ahead of a potential EU approval in 2H26. Pipeline timelines were reiterated and we look forward to the final data from the phase 3 trial for MaaT013 in aGvHD for confirmation of the initial survival data reported in January 2025 (54% at 1-year). Beyond aGvHD, data from the phase 2 trial of MaaT013 in combination with ICI in metast...
- Guy Sips
- Mathijs Geerts Danau
- Michiel Declercq
- Wim Hoste
- Guy Sips
- Hilde Van Boxstael
- Kristof Samoy
- Lynn Hautekeete
- Wim Lewi
- Kristof Samoy
Ekopak First look: 1H25 disappoints, cautious outlook, no update on Wa...
1H25 revenues landed at €21.7m considerably below our €36m estimate. Adj. EBITDA stands at €-3.8m compared to our €+3.5m forecast. Segment reporting has changed and company no longer reports WaaS and non-WaaS but now differentiates the numbers between project and recurring business. FY25 guidance was issued and cautiously calls for growth in turnover vs. 2024. The 2025 outlook does not include any projections for Waterkracht on which the company will issue a separate update when relevant. Compan...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
- Wim Hoste
Recticel Conference call feedback & model update
Recticel has posted solid double digit top line growth in 1H25 with a flattish adj EBITDA margin. The € 27.7m adj EBITDA figure was c. 8% below our forecast and 7% below consensus. The fresh FY25 adjusted EBITDA guidance calls for c. 10% growth which was below our and consensus forecasts (of c. +24%). Positive is that building permit levels are starting to pick up in some geographies. The strategic growth projects in the US (Insulated Panels Plant) and Belgium (Recycling plant) are progressing a...
- ING Helpdesk
Benelux Morning Notes
Ackermans & van Haaren: A strong 1H25. Avantium: Nearly there. Eurocommercial Properties: Good results, positive effects of remerchandising. Recticel: Weak 1H25 calls for a 12% downgrade to consensus at Adj. EBITDA level. Sif Group: 2025 and 2026 guidance cuts. Staffing: Belgium - July Temp volume weaker at -3.5% YoY despite easier comps
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Lynn Hautekeete
- Wim Hoste
- Wim Lewi
- Wim Hoste
Recticel FIRST LOOK: 1H adj.EBITDA +10%, FY EBITDA growth guidance of ...
Recticel has posted solid double digit top line growth in 1H25 with a flattish adj EBITDA margin. The € 27.7m adj EBITDA figure was c. 8% below our forecast and 7% below consensus. The fresh FY25 adjusted EBITDA guidance calls for c. 10% growth which is below our and consensus forecasts (of c. +24%). Positive is that building permit levels are starting to pick up in some geographies. The strategic growth projects in the US (Insulated Panels Plant) and Belgium (Recycling plant) are progressing ac...
- Hilde Van Boxstael
- Kristof Samoy
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Wim Lewi
- ING Helpdesk
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.